Skip to content

US · PRENW · HOUSEHOLD & PERSONAL PRODUCTS

Prenetics Global Limited (PRENW) intrinsic value and stock valuation

$0.02as of 2026-09-18 · Mkt cap 376.31M

Data updated · price as of 2026-09-18

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Prenetics Global Limited DCF and intrinsic value

InvestorsCraft values PRENW with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from PRENW’s statements →

Prenetics Global Limited Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Consumer Defensive · Household & Personal Products Hong Kong, HK prenetics.com

How the business is doing

Fiscal 2025–2019, USD

Revenue
$9.23T-21.3% 5y CAGRd
20252019
Net income
-$-20.14T
20252019
Free cash flow
-$-2.26T
20252019
Total equity
$16.9T-37.1% 5y CAGRd
20252019

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2025–2019, USD
FYFYFYFYFY
Revenue$92.4T$30.6T$21.7T$13.2T$12.5T
Operating income-$-38.13T-$-48.14T-$-51.91T-$-66.02T-$-56.66T
Net income-$-37.71T-$-46.3T-$-62.72T-$-190.45T-$-174.01T
EPSd-$-2.68M-$-3.64M-$-5.58M-$-37.57M-$-47.04M
Operating cash flow-$-21.81T-$-28.87T-$-13.76T$14.5T$13.4T
Capital expenditure-$-208B-$-1.07T-$-911.81B-$-6.34T-$-11.41T
Free cash flow-$-22.02T-$-29.94T-$-14.68T$8.17T$2T
Total assets$203.5T$213.6T$254.2T$312.1T$148.5T
Total debt$2.2T$5.77T$2.37T$6.65T$491.7T
Net debt-$-29.93T-$-46.48T-$-43.34T-$-140.01T$456.4T
Total equity$174.5T$171.3T$210.2T$243.5T-$-400.89T
Cash and short-term investments$61.5T$62.8T$72.7T$184.1T$45.2T
Income statement
FYFYFYFYFY
Revenue$92.4T$30.6T$21.7T$13.2T$12.5T
Cost of revenue$43.6T$15.2T$12.9T$9.55T$8.93T
Gross profit$48.8T$15.4T$8.83T$3.62T$3.6T
Research and development expenses$5.13T$10.9T$11.7T$5.99T$6.39T
Selling, general and administrative expenses$79.8T$55.4T$49.7T$64.1T$53.7T
Other expenses$1.99T-$-2.75T-$-606.84B-$-430B$202.2B
Operating expenses$86.9T$63.5T$60.7T$69.6T$60.3T
Cost and expenses$130.5T$78.8T$73.6T$79.2T$69.2T
Interest income$1.04T$2.04T$3.92T$472B$201M
Interest expense$241B$203B$119.7B$242B$42.2B
Depreciation and amortization$3.78T$5.93T$7.79T$7.54T$7.35T
Ebitda-$-32.19T-$-51.57T-$-47.9T-$-218.04T-$-209.16T
Operating income-$-38.13T-$-48.14T-$-51.91T-$-66.02T-$-56.66T
Total other income/expenses, net$1.92T-$-9.56T-$-4.76T-$-159.8T-$-159.89T
Income before tax-$-36.21T-$-57.7T-$-56.67T-$-225.82T-$-216.55T
Income tax expense$34B-$-7.87T-$-269.36B-$-245B$2.57T
Net income-$-37.71T-$-46.3T-$-62.72T-$-190.45T-$-174.01T
Weighted average shares outstanding$14.1T$12.7T$11.2T$5.07T$3.7T
Weighted average diluted shares outstanding$14.1T$12.7T$11.2T$5.07T$3.7T
Balance sheet
FYFYFYFYFY
Cash and short-term investments$61.5T$62.8T$72.7T$184.1T$45.2T
Net receivables$2.98T$5.61T$5.29T$42.5T$47.1T
Inventory$7.06T$6.57T$3.13T$4.53T$6.83T
Total current assets$83.4T$86.1T$93.7T$241.8T$106.9T
Property, plant and equipment, net$1.76T$7.81T$5.78T$13.1T$13T
Goodwill and intangible assets$44.7T$48.9T$42.6T$48.6T$27.8T
Long-term investments$67T$69.3T$107.8T$788.5B$0.00
Total non-current assets$120.1T$127.4T$160.5T$70.3T$41.6T
Total assets$203.5T$213.6T$254.2T$312.1T$148.5T
Accounts payable$7.73T$3.67T$1.67T$7.29T$9.98T
Short-term debt$1.33T$2.76T$1.5T$2.88T$1.67T
Deferred revenue$3.09T$6.49T$6.11T$5.67T$9.59T
Total current liabilities$27.7T$36.6T$39.5T$57.2T$58.7T
Long-term debt$874B$3.01T$867B$3.76T$490T
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$1.34T$5.68T$4.53T$11.5T$490.7T
Capital lease obligations$437B$5.77T$2.37T$6.65T$3.6T
Total liabilities$29T$42.2T$44T$68.7T$549.4T
Common stock$25B$19B$18B$13.7B$1.49B
Retained earnings$0.00-$-517.07T-$-470.77T-$-408.04T$0.00
Accumulated other comprehensive income (loss)$0.00-$-169.25T-$-176.03T-$-185.69T-$-400.81T
Total equity$174.5T$171.3T$210.2T$243.5T-$-400.89T
Total investments$96.4T$79.9T$134.9T$38.2T$9.91T
Total debt$2.2T$5.77T$2.37T$6.65T$491.7T
Net debt-$-29.93T-$-46.48T-$-43.34T-$-140.01T$456.4T
Cash flow statement
FYFYFYFYFY
Net income-$-52.7T-$-49.81T-$-64.78T-$-190.45T-$-174.02T
Depreciation and amortization$3.78T$5.93T$7.79T$7.54T$7.35T
Stock-based compensation$0.00$12T$10.6T$31.6T$22.5T
Change in working capital$6.62T$1.97T$24.2T-$-33.76T-$-6.59T
Accounts receivable-$-529B-$-428B$37.6T$6.97T-$-24.06T
Inventory-$-3.38T$1.32T-$-1.73T$1.26T-$-2.33T
Accounts payable$4.91T-$-4.68T-$-5.62T-$-2.63T-$-3.46T
Net cash provided by operating activities-$-21.81T-$-28.87T-$-13.76T$14.5T$13.4T
Investments in property, plant and equipment-$-54.56T-$-1.01T-$-345.29B-$-6.34T-$-8.55T
Acquisitions, net$37.8T$21.7T$0.00-$-3.42T$0.00
Net cash used for investing activities-$-35.79T$38.5T-$-82.95T-$-46.14T-$-22.02T
Common stock issued$2B$0.00$2.17B$116.9B$0.00
Common stock repurchased$0.00-$-577B-$-1.23T-$-661.52B$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$37.5T-$-3.34T-$-4.7T$143.3T$29.3T
Net change in cash-$-20.12T$6.55T-$-100.95T$111.4T$20.8T
Cash at end of period$32.1T$52.3T$45.7T$146.7T$35.3T
Operating cash flow-$-21.81T-$-28.87T-$-13.76T$14.5T$13.4T
Capital expenditure-$-208B-$-1.07T-$-911.81B-$-6.34T-$-11.41T
Free cash flow-$-22.02T-$-29.94T-$-14.68T$8.17T$2T
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Prenetics Global Limited

        Prenetics Global Limited operates as an investment holding company specializing in diagnostics and genetic testing. Its core offerings include CircleDNA, a consumer genetic testing solution, and the Circle HealthPod, a rapid detection health monitoring system that enables users to perform point-of-care or at-home COVID-19 tests using nucleic acid amplification technology. The company's portfolio further comprises ColoClear, a non-invasive FIT-DNA colorectal cancer screening test; Circle SnapShot, an accessible at-home blood testing kit; and Circle Medical, a diagnostic testing platform. Other products include Circle One, F1x, and Fem. Established in 2014, Prenetics Global Limited is headquartered in Quarry Bay, Hong Kong.

        CEO
        Sheng Wu Yeung
        Employees
        98
        Beta
        0.25

        Explore

        Frequently asked questions

        What is the intrinsic value of Prenetics Global Limited (PRENW)?

        InvestorsCraft does not currently publish an intrinsic value for PRENW. How the IC value is calculated.

        Is PRENW undervalued?

        InvestorsCraft does not publish an undervaluation signal for PRENW at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Sep 19, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.